売上高・売上総利益率の推移
| 年度 |
売上高 |
売上総利益率 |
| 2016/12 |
144,273 |
- |
| 2015/12 |
89,258 |
- |
| 2014/12 |
102,756 |
- |
| 2013/12 |
47,786 |
- |
| 2012/12 |
48,921 |
- |
営業利益・営業利益率の推移
| 年度 |
営業利益 |
営業利益率 |
| 2023/12 |
-2,037 |
- |
| 2022/12 |
-1,729 |
- |
| 2021/12 |
-2,472 |
- |
| 2020/12 |
-2,873 |
- |
| 2019/12 |
-22,359 |
- |
| 2018/12 |
-65,575 |
- |
| 2017/12 |
-95,766 |
- |
| 2016/12 |
-110,141 |
-76.3% |
| 2015/12 |
-129,571 |
-145.2% |
| 2014/12 |
-66,256 |
-64.5% |
| 2013/12 |
-120,540 |
-252.2% |
| 2012/12 |
-92,742 |
-189.6% |
|
(単位:千ドル)
|
2012/12
|
2013/12
|
2014/12
|
2015/12
|
2016/12
|
2017/12
|
2018/12
|
2019/12
|
2020/12
|
2021/12
|
2022/12
|
2023/12
|
|
売上高
|
48,921
|
47,786
|
102,756
|
89,258
|
144,273
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
売上成長率(%)
|
-
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
売上原価
|
-
|
-
|
-
|
46
|
6,912
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
研究開発費
|
125,858
|
147,139
|
138,495
|
160,988
|
160,917
|
67,314
|
49,974
|
11,100
|
-
|
-
|
-
|
-
|
|
販売管理費
|
-
|
-
|
-
|
57,795
|
80,729
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
営業費用
|
141,663
|
168,326
|
169,012
|
218,829
|
254,414
|
95,766
|
65,575
|
22,359
|
2,873
|
2,472
|
1,729
|
2,037
|
|
営業利益
|
-92,742
|
-120,540
|
-66,256
|
-129,571
|
-110,141
|
-95,766
|
-65,575
|
-22,359
|
-2,873
|
-2,472
|
-1,729
|
-2,037
|
|
営業利益率 (%)
|
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
経常(税引前)利益
|
-
|
-
|
-
|
-
|
-
|
-118,403
|
-68,462
|
-22,740
|
-3,014
|
-2,452
|
-1,541
|
-1,169
|
|
法人税等合計
|
-
|
-
|
-
|
-
|
-
|
-42,399
|
-7,695
|
-1,473
|
14
|
3
|
3
|
12
|
|
実効税率(%)
|
-
|
-
|
-
|
-
|
-
|
|
|
6.5
|
-0.5
|
-0.1
|
-0.2
|
-1.0
|
|
純利益
|
-91,277
|
-130,685
|
-83,291
|
-147,787
|
-151,740
|
472,028
|
-40,506
|
-17,332
|
-3,028
|
-2,455
|
-1,544
|
-1,181
|
|
純利益率(%)
|
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
一株あたり利益
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.11
|
-0.08
|
|
希薄化後一株あたり利益
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.11
|
-0.08
|
|
一株あたり配当金
|
-
|
-
|
-
|
-
|
-
|
10.55
|
-
|
2
|
-
|
-
|
-
|
-
|
|
EBITDA
|
|
|
|
|
|
|
|
-20,131
|
-
|
-
|
-
|
-
|
|
EBITDAマージン(%)
|
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|